1.25
price up icon9.65%   0.11
after-market After Hours: 1.24 -0.01 -0.80%
loading
Ocugen Inc stock is traded at $1.25, with a volume of 4.08M. It is up +9.65% in the last 24 hours and up +0.00% over the past month. Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.14
Open:
$1.15
24h Volume:
4.08M
Relative Volume:
0.76
Market Cap:
$359.82M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.3784
EPS:
-0.37
Net Cash Flow:
$-72.53M
1W Performance:
-3.85%
1M Performance:
+0.00%
6M Performance:
+26.52%
1Y Performance:
+201.35%
1-Day Range:
Value
$1.13
$1.25
1-Week Range:
Value
$1.12
$1.30
52-Week Range:
Value
$0.345
$2.105

Ocugen Inc Stock (OCGN) Company Profile

Name
Name
Ocugen Inc
Name
Phone
484-328-4701
Name
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Employee
84
Name
Twitter
@Ocugen
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
OCGN's Discussions on Twitter

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-01-23 Upgrade Chardan Capital Markets Neutral → Buy
Aug-23-22 Initiated Mizuho Buy
Jun-15-22 Resumed ROTH Capital Buy
Jun-02-22 Initiated Cantor Fitzgerald Overweight
Jul-26-21 Initiated Noble Capital Markets Outperform
Jun-11-21 Downgrade ROTH Capital Buy → Neutral
May-07-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21 Downgrade Chardan Capital Markets Buy → Neutral
Feb-04-21 Upgrade H.C. Wainwright Neutral → Buy
View All

Ocugen Inc Stock (OCGN) Latest News

pulisher
06:44 AM

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - Ocugen

06:44 AM
pulisher
06:31 AM

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to - GlobeNewswire

06:31 AM
pulisher
06:30 AM

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - StockTitan

06:30 AM
pulisher
Sep 08, 2024

Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN

Sep 08, 2024
pulisher
Sep 07, 2024

Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MyChesCo

Sep 07, 2024
pulisher
Sep 06, 2024

Ocugen Inc. stock falls Friday, underperforms market - MarketWatch

Sep 06, 2024
pulisher
Sep 06, 2024

Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MSN

Sep 06, 2024
pulisher
Sep 05, 2024

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

Sep 05, 2024
pulisher
Sep 05, 2024

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - GlobeNewswire

Sep 05, 2024
pulisher
Sep 05, 2024

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit - StockTitan

Sep 05, 2024
pulisher
Sep 05, 2024

Ocugen, Inc. to Engage Investors at H.C. Wainwright Conference - MyChesCo

Sep 05, 2024
pulisher
Sep 04, 2024

Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch

Sep 04, 2024
pulisher
Sep 03, 2024

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Ocugen

Sep 03, 2024
pulisher
Sep 03, 2024

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 03, 2024
pulisher
Aug 30, 2024

Ocugen Inc. stock rises Friday, outperforms market - MarketWatch

Aug 30, 2024
pulisher
Aug 29, 2024

Ocugen Advances Gene Therapy Trial for Stargardt Disease - MSN

Aug 29, 2024
pulisher
Aug 29, 2024

Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch

Aug 29, 2024
pulisher
Aug 29, 2024

Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Decreases By 19.9% - MarketBeat

Aug 29, 2024
pulisher
Aug 28, 2024

TSX Information Tech Capped Index (TTTK) QuotePress Release - The Globe and Mail

Aug 28, 2024
pulisher
Aug 28, 2024

TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen Advances Gene Therapy Trial for Stargardt Disease - MyChesCo

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen Announces Completion of Dosing in Subjects with - GlobeNewswire

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen rises on completing patient dosing in early-stage gene therapy trial - XM

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen completes dosing in Stargardt disease trial - Investing.com

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - Ocugen

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - GlobeNewswire

Aug 28, 2024
pulisher
Aug 28, 2024

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - StockTitan

Aug 28, 2024
pulisher
Aug 27, 2024

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up - MSN

Aug 27, 2024
pulisher
Aug 27, 2024

Ocugen Expands Gene Therapy Trial to Canada - MSN

Aug 27, 2024
pulisher
Aug 27, 2024

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Aug 27, 2024
pulisher
Aug 27, 2024

Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up - Yahoo Finance

Aug 27, 2024
pulisher
Aug 26, 2024

Ocugen Inc. stock rises Monday, outperforms market - MarketWatch

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen advances gene therapy trial for retinitis pigmentosa - Investing.com

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen Gets Health Canada Approval for Phase 3 Trial of Gene Therapy for Retinitis Pigmentosa - MarketWatch

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen advances gene therapy trial for retinitis pigmentosa - Investing.com India

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Ocugen

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Yahoo Finance UK

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Yahoo Finance

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - GlobeNewswire

Aug 26, 2024
pulisher
Aug 26, 2024

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - StockTitan

Aug 26, 2024
pulisher
Aug 15, 2024

OCGN (Ocugen) Enterprise Value : $348.11 Mil (As of Aug. 17, 2024) - GuruFocus.com

Aug 15, 2024
pulisher
Aug 15, 2024

Reviewing Sutro Biopharma (NASDAQ:STRO) and Ocugen (NASDAQ:OCGN) - Defense World

Aug 15, 2024
pulisher
Aug 14, 2024

Chardan Capital Weighs in on Ocugen, Inc.'s FY2024 Earnings (NASDAQ:OCGN) - MarketBeat

Aug 14, 2024
pulisher
Aug 14, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - Longview News-Journal

Aug 14, 2024
pulisher
Aug 14, 2024

OCGN Investors Have Opportunity to Lead Ocugen, Inc. Securities Fraud Lawsuit - Longview News-Journal

Aug 14, 2024
pulisher
Aug 14, 2024

Chardan Capital Research Analysts Raise Earnings Estimates for Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Aug 14, 2024
pulisher
Aug 14, 2024

Financial Contrast: Ocugen (NASDAQ:OCGN) & ZIVO Bioscience (NASDAQ:ZIVO) - Defense World

Aug 14, 2024
pulisher
Aug 13, 2024

Ocugen Inc. stock rises Tuesday, still underperforms market - MarketWatch

Aug 13, 2024
pulisher
Aug 12, 2024

Ocugen, Inc. Forecasted to Post Q4 2024 Earnings of ($0.06) Per Share (NASDAQ:OCGN) - MarketBeat

Aug 12, 2024
pulisher
Aug 12, 2024

Tidal Investments LLC Purchases Shares of 66,009 Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Aug 12, 2024

Ocugen Inc Stock (OCGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.33
price up icon 0.30%
$27.46
price down icon 0.22%
$193.31
price up icon 1.04%
$100.53
price up icon 11.77%
$76.61
price up icon 5.10%
$253.16
price up icon 2.59%
Cap:     |  Volume (24h):